1. Noninvasive assessment of liver fibrosis in Crohn’s disease patients exposed to methotrexate.
Llaó J., Masnou H., Romero C., et al. [published online ahead of print, 2020 Aug 14]. Eur J Gastroenterol Hepatol. 2020;10.1097/MEG.0000000000001799. doi:10.1097/MEG.0000000000001799
2. Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character)
Vatn S., Carstens A., Kristoffersen A.B., et al. [published online ahead of print, 2020 Aug 11]. Scand J Gastroenterol. 2020;1-11. doi:10.1080/00365521.2020.1803396
3. Ultrasound findings of Crohn’s disease: correlation with MR enterography.
Gonzalez-Montpetit E., Ripollés T., Martinez-Pérez M.J., Vizuete J., Martín G., Blanc E. [published online ahead of print, 2020 Jun 30]. Abdom Radiol (NY). 2020;10.1007/s00261-020-02622-3. doi:10.1007/s00261-020-02622-3
4. Gastrointestinal infection with Aeromonas: incidence and relationship to inflammatory bowel disease.
Elorza A., Rodríguez-Lago I., Martínez P., Hidalgo A., Aguirre U., Cabriada J.L. [published online ahead of print, 2020 Jul 21]. Gastroenterol Hepatol. 2020;S0210-5705(20)30238-7. doi:10.1016/j.gastrohep.2020.04.014
5. Evaluation of Crohn’s Disease Activity: Development of an Ultrasound Score in a Multicenter Study.
Ripollés T., Poza J., Suarez Ferrer C., Martínez-Pérez M.J., Martín-Algíbez A., de Las Heras, Paez B. [published online ahead of print, 2020 Jun 8]. Inflamm Bowel Dis. 2020;izaa134. doi:10.1093/ibd/izaa134
6. Early microscopic findings in preclinical inflammatory bowel disease.
Rodríguez-Lago I., Ramírez C., Merino O., et al. [published online ahead of print, 2020 Jun 26]. Dig Liver Dis. 2020;S1590-8658(20)30263-2. doi:10.1016/j.dld.2020.05.052
7. Leishmania infantum asymptomatic infection in inflammatory bowel disease patients under anti-TNF therapy.
Guillén M.C., Alcover M.M., Borruel N., et al. Heliyon. 2020;6(5):e03940. Published 2020 May 8. doi:10.1016/j.heliyon.2020.e03940
8. Relevance of dynamic studies with magnetic resonance enterography in Crohn’s disease.
Pous S., Frasson M., Jiménez R., et al. Gastroenterol Hepatol. 2020;43(4):179-187. doi:10.1016/j.gastrohep.2019.11.010
9. Validation of the simplified Magnetic Resonance Index of Activity (sMARIA) without gadolinium-enhanced sequences for Crohn’s disease.
Capozzi N., Ordás I., Fernandez-Clotet A., et al. [published online ahead of print, 2020 Feb 21]. J Crohns Colitis. 2020;jjaa030. doi:10.1093/ecco-jcc/jjaa030
10. Crohn’s Disease and Immunosupressive Treatment: Hepatosplenic Lesions as an Atypical Case of Bartonella henselae.
García M.J., Armiñanzas C., Rivero M., Ramos M. Inflamm Bowel Dis. 2020;26(3):e17-e18. doi:10.1093/ibd/izz318
11. Comparison of small-bowel colon capsule endoscopy system to conventional colonoscopy for the evaluation of ulcerative colitis activity.
Adler S.N., González Lama Y., Matallana Royo V., Suárez Ferrer C., Schwartz A., Bar-Gil Shitrit A. Endosc Int Open. 2019;7(10):E1253-E1261. doi:10.1055/a-0982-2786
12. Usefulness of magnetic resonance enterography in the clinical decision-making process for patients with inflammatory bowel disease.
Ramos López L., Hernández Camba A., Rodríguez-Lago I., et al. [published online ahead of print, 2020 Apr 26]. Gastroenterol Hepatol. 2020;S0210-5705(20)30111-4. doi:10.1016/j.gastrohep.2020.03.007
13. Spontaneous hepatic portal venous gas in a patient with ulcerative colitis. A case report and a review.
Murzi M., Gordillo J., Oblitas E., et al. Gastroenterol Hepatol. 2020;43(1):22-25. doi:10.1016/j.gastrohep.2019.08.004